Dutasteride/Tamsulosin Shortage: What Providers and Prescribers Need to Know in 2026

Dutasteride/tamsulosin (Jalyn) is not currently listed on the FDA's official drug shortage database, but prescribers and pharmacists across the country are encountering localized stocking challenges with this fixed-dose combination product. For urologists and primary care providers managing patients with benign prostatic hyperplasia (BPH), this guide summarizes what's driving availability issues, how to counsel patients, and how to adapt treatment plans when the combination product is unavailable.

Clinical Background: The CombAT Evidence Base

Dutasteride/tamsulosin (Jalyn) is FDA-approved for symptomatic BPH in men with an enlarged prostate. The drug was approved in June 2010 based on two-year data from the CombAT (Combination of Avodart and Tamsulosin) trial — a four-year, randomized, double-blind study enrolling 4,844 men aged ≥50 with moderate-to-severe BPH symptoms (IPSS ≥12), prostate volume ≥30 cc, and PSA 1.5–10 ng/mL.

Key four-year CombAT results:

Combination reduced risk of AUR or BPH-related surgery by 66% vs tamsulosin monotherapy (p<0.001)

Reduced BPH clinical progression by 44% vs tamsulosin and 31% vs dutasteride alone

Mean IPSS change at 24 months: −6.2 (combination) vs −4.9 (dutasteride) vs −4.3 (tamsulosin)

Adverse events: combination group had 28% drug-related adverse events vs 21% dutasteride, 19% tamsulosin; withdrawal rates were similar (6%, 4%, 4%)

Current Supply Situation

No FDA shortage declaration exists for dutasteride/tamsulosin as of 2026. Multiple generic manufacturers produce the 0.5 mg/0.4 mg combination capsule. However, because prescription volume for the fixed-dose combination is lower than for the individual components — many prescribers and patients use separate generic dutasteride and tamsulosin — some retail pharmacies stock the combination in limited quantities or do not carry it routinely. Patients may need to try multiple pharmacies or request special orders.

Substitution Strategy: Prescribing the Components Separately

The most clinically appropriate and logistically simple substitution when Jalyn is unavailable is to prescribe the individual generics:

Dutasteride 0.5 mg capsules — once daily, with or without food

Tamsulosin HCl 0.4 mg capsules — once daily, approximately 30 minutes after the same meal

This is therapeutically identical to Jalyn (the same doses used in the CombAT trial) and both individual generics are among the most widely stocked medications in U.S. retail pharmacies. The two-prescription approach may also be beneficial for patients experiencing side effects attributable to one component — allowing dose modification or discontinuation of a single agent.

Alternative 5-ARI: Finasteride

If a 5-ARI switch is clinically appropriate, finasteride 5 mg daily is a reasonable alternative to dutasteride. Important prescribing considerations:

Both medications reduce PSA by approximately 50% after 3–6 months; establish a new baseline PSA at 3–6 months post-switch

Dutasteride's very long half-life (~5 weeks) means serum levels persist for months after discontinuation — inform patients and adjust PSA interpretation accordingly

Finasteride inhibits only type 2 5-alpha reductase; dutasteride inhibits both type 1 and type 2. Clinically, both have similar BPH outcomes in head-to-head trials (EPICS study)

Finasteride is significantly less expensive — generic finasteride 5 mg is as low as $6/month with GoodRx

39,333+ patients found their medications in stock

39K+

Find Dutasteride/Tamsulosin In Stock Today →

Alternative Alpha-Blockers

If tamsulosin must be substituted, the following alpha-1 blockers are FDA-approved for BPH:

Silodosin (Rapaflo) 8 mg daily — Highest alpha-1A selectivity; high rate of retrograde ejaculation (~28%)

Alfuzosin (Uroxatral) 10 mg daily — Lower ejaculatory dysfunction risk; good option for sexually active men

Doxazosin (Cardura) 1–8 mg daily — Non-selective; dual benefit for BPH + hypertension; requires titration

PSA Monitoring Considerations

Any dutasteride-containing regimen (including Jalyn) reduces serum PSA by approximately 50% within 3–6 months. This reduction is predictable and does not preclude prostate cancer detection — clinicians should double the observed PSA to estimate the true value if using PSA for cancer screening in patients on 5-ARI therapy. Establish a new PSA baseline at least 3 months after initiating or switching 5-ARI therapy. Percent free PSA is not affected and does not require adjustment.

Skip the calls, skip the stress.

Find Dutasteride/Tamsulosin In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Blood Donation Restriction

Counsel all patients on dutasteride-containing products (including Jalyn) that they must not donate blood until at least 6 months after their last dose. This is to prevent inadvertent dutasteride exposure to pregnant female transfusion recipients, as dutasteride can inhibit normal male fetal genital development if absorbed through the skin.

Helping Patients Find Dutasteride/Tamsulosin in Stock

For patients who specifically need the combination product, refer them to medfinder.com/providers. medfinder calls pharmacies near a patient's location to check which ones have a specific medication in stock, then texts results directly to the patient — eliminating the need for repeated phone calls and reducing treatment gaps.